Literature DB >> 29242303

Ibrutinib does not affect ristocetin-induced platelet aggregation evaluated by light transmission aggregometry in chronic lymphocytic leukemia patients.

Maria Adele Alberelli1, Idanna Innocenti2, Francesco Autore2, Luca Laurenti2, Erica De Candia3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29242303      PMCID： PMC5830396          DOI： 10.3324/haematol.2017.179044

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  13 in total

1.  Bleeding diathesis associated with acquired von Willebrand Syndrome in three patients with chronic lymphocytic leukemia.

Authors:  Mona Lisa Alattar; Maria Ciccone; Mahmoud R Gaballa; Candida Vitale; Xavier C Badoux; George Manoukian; Michael J Keating; Michael H Kroll; Alessandra Ferrajoli
Journal:  Leuk Lymphoma       Date:  2015-05-26

2.  Distinct pathways regulate Syk protein activation downstream of immune tyrosine activation motif (ITAM) and hemITAM receptors in platelets.

Authors:  Bhanu Kanth Manne; Rachit Badolia; Carol Dangelmaier; Johannes A Eble; Wilfried Ellmeier; Mark Kahn; Satya P Kunapuli
Journal:  J Biol Chem       Date:  2015-03-12       Impact factor: 5.157

Review 3.  Ibrutinib-associated bleeding: pathogenesis, management and risk reduction strategies.

Authors:  J J Shatzel; S R Olson; D L Tao; O J T McCarty; A V Danilov; T G DeLoughery
Journal:  J Thromb Haemost       Date:  2017-03-27       Impact factor: 5.824

4.  Recommendations for the Standardization of Light Transmission Aggregometry: A Consensus of the Working Party from the Platelet Physiology Subcommittee of SSC/ISTH.

Authors:  M Cattaneo; C Cerletti; P Harrison; C P M Hayward; D Kenny; D Nugent; P Nurden; A K Rao; A H Schmaier; S P Watson; F Lussana; M T Pugliano; A D Michelson
Journal:  J Thromb Haemost       Date:  2013-04-10       Impact factor: 5.824

5.  Comment on Lipsky et al.: Incidence and Risk Factors of Bleeding-Related Adverse Events in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib.

Authors:  Constantine S Tam; Sarah Kamel
Journal:  Haematologica       Date:  2016-03       Impact factor: 9.941

6.  Bruton tyrosine kinase is essential for botrocetin/VWF-induced signaling and GPIb-dependent thrombus formation in vivo.

Authors:  Junling Liu; Malinda E Fitzgerald; Michael C Berndt; Carl W Jackson; T Kent Gartner
Journal:  Blood       Date:  2006-06-20       Impact factor: 22.113

7.  Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation.

Authors:  S Kamel; L Horton; L Ysebaert; M Levade; K Burbury; S Tan; M Cole-Sinclair; J Reynolds; R Filshie; S Schischka; A Khot; S Sandhu; M J Keating; H Nandurkar; C S Tam
Journal:  Leukemia       Date:  2014-08-20       Impact factor: 11.528

8.  Variables influencing Multiplate(TM) whole blood impedance platelet aggregometry and turbidimetric platelet aggregation in healthy individuals.

Authors:  Ulrich Theo Seyfert; Hannelore Haubelt; Anette Vogt; Peter Hellstern
Journal:  Platelets       Date:  2007-05       Impact factor: 3.862

9.  A role for Bruton's tyrosine kinase (Btk) in platelet activation by collagen.

Authors:  L S Quek; J Bolen; S P Watson
Journal:  Curr Biol       Date:  1998-10-08       Impact factor: 10.834

10.  Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions.

Authors:  Marie Levade; Elodie David; Cédric Garcia; Pierre-Alexandre Laurent; Sarah Cadot; Anne-Sophie Michallet; Jean-Claude Bordet; Constantine Tam; Pierre Sié; Loïc Ysebaert; Bernard Payrastre
Journal:  Blood       Date:  2014-10-10       Impact factor: 22.113
View more
  1 in total

Review 1.  Autoimmune disorders of platelet function: systematic review of cases of acquired Glanzmann thrombasthenia and acquired delta storage pool disease.

Authors:  Monica Bacci; Antonietta Ferretti; Marina Marchetti; Maria A Alberelli; Anna Falanga; Corrado Lodigiani; Erica De Candia
Journal:  Blood Transfus       Date:  2022-01-08       Impact factor: 5.752
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.